Can DNA glitches predict prostate cancer treatment success?

NCT ID NCT04489719

Recruiting now Knowledge-focused Sponsor: University of Washington Source: ClinicalTrials.gov ↗

First seen Feb 20, 2026 · Last updated May 28, 2026 · Updated 17 times

Summary

This study looks at men with advanced prostate cancer that has spread to the bones. Researchers want to see if certain DNA repair problems in the cancer cells make the drug radium-223 work better or worse. The goal is to help doctors choose the best treatment for each patient in the future. About 48 men will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Bozeman Health Deaconess Hospital
ACTIVE_NOT_RECRUITING

Bozeman, Montana, 59715, United States
Fred Hutch/University of Washington Cancer Consortium
RECRUITING

Seattle, Washington, 98109, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
Johns Hopkins University
RECRUITING

Baltimore, Maryland, 21287, United States

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
University of Wisconsin-Madison
RECRUITING

Madison, Wisconsin, 53705, United States

Contact

Conditions

Explore the condition pages connected to this study.

CASTRATION-RESISTANT PROSTATE CARCINOMA METASTATIC MALIGNANT NEOPLASM IN THE BONE METASTATIC PROSTATE CARCINOMA STAGE IVB PROSTATE CANCER AJCC V8 STAGE IVB PROSTATE CANCER AJCC V8